EN DE
Watch Imunon, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Imunon, Inc (IMNN) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Imunon, Inc stock $0.51, price $0.63, that is 19.1% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US15117N7012

II Imunon, Inc logo Thin data Nov 16, 2026

Imunon, Inc

IMNN · US

Expensive (fair value 19% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Quality 40/100 
Moderate debt 
Insiders sold $38,127 (6M) 
Fair value $0.5097 · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −24.2 %/yr in USD) 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 9/100
Thin data 
Estimate
Watch Imunon, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$185.44 $0.6300 Fair Value $0.5097 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $0.6300 – $185.44 · fair‑value band $0.3823 – $0.6371 · the $0.6300 price screens above the $0.5097 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Imunon in your weekly email

Every Wednesday you see whether Imunon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States.

Show moreShow less

The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.

It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial.

In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.

The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.

Stock analysis

Imunon, Inc (IMNN) currently trades at $0.6300, while our estimate is $0.5097, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.3823 (bear) to $0.6371 (bull), the price of $0.6300 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Imunon, Inc reported revenue of $0 in FY2025 versus $500K in FY2021. Reported net income was −$14.5M in FY2025.

Key figures

Market cap $4.1M Micro · P/S ratio 32.6 · EPS (TTM) $−3.31 · Return on equity −430% · Return on assets (EBIT) −99.4% (5-year average) · Revenue (TTM) $125K · Free cash flow −$14.2M · Net cash $7.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 85% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −19%, IMNN screens richer than that median.

Fair Value

Bear $0.3823 Fair Value $0.5097 Bull $0.6371
Price $0.6300 · Downside -19.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 31
Do the profits arrive as real cash?
Financial strength 61
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $38,127 and none bought.

  • SaleSusan EylwardGeneral Counsel and Corp Sec6× since Jun 29, 2026: 22,385 shares, avg. $1.70$38,127Aug 31, 2026

Plus 57 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−75.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.2%
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,213.0% (2018) → −16,824.3% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IMNN screens overvalued: fair value 19% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Imunon, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside −19.1% · Above median
Profitability
Return on assets −118.0% · Bottom 25%
Balance sheet
Debt / equity 0.65× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.58× · Cheapest 25%
P/S (12 months) 32.64× · Priciest 25%
PEG 5.03× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)8 · sector 0
FUTURE (revenue growth)0 · sector 34
PAST (return on equity)0 · sector 0
HEALTH (low debt)67 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs IMNN
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs IMNN
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs IMNN
argenx SE ARGX $960.04 $908.40 −5% vs IMNN
CSL Limited CSL A$202.52 A$185.51 −8% vs IMNN
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs IMNN
Moderna, Inc MRNA $223.37 $135.64 −39% vs IMNN
Revolution Medicines, Inc RVMD $172.29 $88.78 −48% vs IMNN
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs IMNN
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs IMNN

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Imunon, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Imunon, Inc Fair Value". https://www.fairvalue-calculator.com/stock/IMNN

Frequently asked questions

Is Imunon, Inc (IMNN) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $0.5097 versus a price of $0.6300, about 19% lower (overvalued).
What is the fair value of IMNN?
Our estimate for Imunon, Inc is $0.5097 (as of Nov 16, 2026), built from audited fundamentals. The current price: $0.6300.
What is the quality score of IMNN?
Imunon, Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Imunon, Inc (IMNN)?
Our calculated price target is the estimate of $0.5097 (as of Nov 16, 2026). Cautious scenario $0.3823, optimistic scenario $0.6371. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Imunon, Inc stock forecast for 2026?
Our estimate puts fair value at $0.5097, about 19% lower versus a price of $0.6300 (overvalued). Cautious scenario $0.3823, optimistic scenario $0.6371. The calculation is refreshed regularly with new filings.
What is the revenue of Imunon, Inc (IMNN)?
Imunon, Inc reported trailing-twelve-month revenue of about $125K (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Imunon, Inc (IMNN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Imunon, Inc it is $0.5097 per share (as of Nov 16, 2026), against a price of $0.6300.
Is Imunon, Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, IMNN trades above its calculated fair value: price $0.6300, fair value $0.5097, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMNN?
No. The price is what the market pays today ($0.6300); the fair value is what the company's own numbers justify ($0.5097). For Imunon, Inc the two are $0.1203 per share apart. That gap is exactly why we show both numbers side by side.
How much is Imunon, Inc worth?
The market values Imunon, Inc at about $4.1M (market capitalisation, as of Nov 16, 2026). Per share that is $0.6300; our models calculate a fair value of $0.5097 per share.
What do the bullish and bearish scenarios say about IMNN?
Our models span a range for Imunon, Inc: cautious scenario $0.3823, base $0.5097, optimistic $0.6371 per share (as of Nov 16, 2026, price $0.6300). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of IMNN?
The PEG ratio of Imunon, Inc is 5.03 (P/E divided by earnings growth, as of Nov 16, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Imunon, Inc (IMNN)?
Balance-sheet figures for Imunon, Inc (as of Nov 16, 2026): return on equity −429.7%, debt of 0.65 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is IMNN from its 52-week high?
Imunon, Inc trades at $0.6300, about 85% below its 52-week high of $4.22 and at the low of $0.6300 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5097 is for.
Which stocks are comparable to Imunon, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Imunon, Inc stock attractive at the current price?
The data as of Nov 16, 2026: price $0.6300, calculated fair value $0.5097 (−19%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Imunon, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Imunon, Inc (IMNN)?
The closing price on Nov 13, 2026 was $0.6300. Our estimate is $0.5097, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Imunon, Inc right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Imunon, Inc

How large is the market capitalisation of Imunon, Inc (IMNN)?
The market capitalisation of Imunon, Inc is $4.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Imunon, Inc (IMNN)?
The price-to-sales ratio of Imunon, Inc is 32.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Imunon, Inc (IMNN)?
Earnings per share at Imunon, Inc are $−3.31. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Imunon, Inc (IMNN)?
The return on equity (ROE) of Imunon, Inc is −430% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Imunon, Inc (IMNN)?
On an EBIT basis the return on assets of Imunon, Inc is −99.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Imunon, Inc (IMNN) generate?
The free cash flow of Imunon, Inc is −$14.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Imunon, Inc (IMNN) hold?
Imunon, Inc holds more cash than debt, $7.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Imunon, Inc in the live analysis

One click puts Imunon, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.